IN8bio, Inc. Common Stock (INAB)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
IN8bio, Inc. Common Stock (INAB) is listed on Nasdaq, where it has traded since July 30, 2021.
- Listed On
- Nasdaq
- Listed Since
- July 30, 2021
- Employees
- 18
- Market Cap
- $13M
About IN8bio, Inc. Common Stock
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 20 institutions reported holding INAB, with 3.8 million shares worth $5.3 million in aggregate. The largest reported holder was Alyeska Investment Group,, with 944,319 shares worth $1.3 million. Of the 5 largest holders listed below, 1 added shares and 4 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Alyeska Investment Group, | 944,319 | $1M | Unchanged |
| Franklin Resources | 914,531 | $1M | Unchanged |
| 683 Capital Management | 724,637 | $1M | Unchanged |
| Stonepine Capital Management | 695,287 | $980K | Added 4.8% |
| Vanguard | 132,435 | $189K | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is INAB?
IN8bio, Inc. Common Stock (INAB) is listed on Nasdaq, where it has traded since July 30, 2021.
Who are the largest institutional holders of INAB?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of INAB were Alyeska Investment Group,, Franklin Resources and 683 Capital Management.
How many institutions own INAB?
20 institutions reported a position in INAB for the quarter ended June 30, 2026, worth $5.3 million in total.
Did institutions buy or sell INAB last quarter?
Of the 5 largest reported holders, 1 added shares and 4 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for INAB.
Every reported institutional holder, plus insider and congressional trades in INAB, on SentiSense.